MC 828 - Hybrid imaging in the male
MC 828 - Hybrid imaging in the maleThursday, March 2, 16:00 - 17:30 Room: M 5 Session Type: Joint Course of ESR and RSNA (Radiological Society of North America): Hybrid Imaging Topics: Nuclear Medicine, Genitourinary, Hybrid imaging Moderators: A. Drzezga (Cologne/DE), K. Riklund (Umea/SE) Add session to my schedule In your schedule (remove)
1. To learn about novel tracer and their biochemical properties.
2. To understand the differences of information given by the use of different tracers.
3. To understand how to interpret examinations with different tracers.
"No abstract submitted."
1. To learn about pathophysiology in prostate cancer.
2. To understand how to interpret hybrid imaging of prostate cancer.
3. To learn about the role of hybrid imaging in staging, treatment evaluation and follow-up.
Currently national and international guidelines for imaging procedures for high-risk and advanced prostate cancer (PCa) include abdomino-pelvic cross sectional imaging, multiparametric prostate MRI, bone scintigraphy and in the case of therapy monitoring of mCRPC whole-body cross-sectional imaging mainly by means of computed tomography. Positron emission tomography (PET) has became increasingly important in the work-up of prostate cancer. In the past, the use was mainly limited to radiolabeled choline-derivatives which showed considerable limitations and did not always meet the diagnostic needs. Recently, a 68 Gallium-labelled ligand of the prostate-specific membrane antigen (68Ga-PSMA) has been introduced in PET-imaging of PCa with first promising results. Due to relatively exclusive expression of PSMA in prostatic tissue as well as increased expression in PCa 68Ga-PSMA was reported to exhibit a favourable lesion to background ratio compared to presently used choline- or fluorodeoxyglucose-based PET examinations. Together with the novel development of combined PET/MR, the combination of excellent morphological detail, multiparametric functional information and molecular PET data might lead to a significant improvement in detection and staging of PCa and thus may help to optimise oncological treatment. The talk encompasses: 1. The molecular basis of prostate cancer imaging targeting the prostate-specific membrane antigen (PSMA), review of the various PSMA-tracers. 2. The diagnostic performance and potential role of PSMA PET/CT and PET/MR for high-risk primary and advanced prostate cancer. 3. Comparison of the use of PSMA PET-imaging with conventional imaging as included in the guidelines.
1. To learn how to interpret hybrid imaging of prostate cancer.
2. To understand the pathophysiology in relation to imaging.
The third part of this session will contain interactive cases based on the previous teaching points.